Form 4: Apogee Therapeutics CFO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Apogee Therapeutics CFO Jane Henderson sold 2,000 shares of common stock at $85 per share under a pre-arranged trading plan.
Summary
- Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc. (APGE), reported a sale of common stock.
- On March 25, 2026, Henderson disposed of 2,000 shares of Apogee Therapeutics common stock.
- The shares were sold at a price of $85 per share.
- This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on September 2, 2025.
- Following this transaction, Henderson beneficially owns 179,371 shares of Apogee Therapeutics common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as neutral. The sale is a routine insider transaction executed under a pre-arranged 10b5-1 plan, which typically minimizes speculative interpretations regarding company performance.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that insider sales, particularly those executed under a Rule 10b5-1 plan, are common and do not necessarily indicate a negative outlook for the company. Such plans are often established by executives to diversify their holdings or manage personal finances over a predetermined period, reducing the risk of accusations of trading on material non-public information.
Stakeholder Impact
- Shareholders: Disclosure of insider trading provides transparency regarding executive stock ownership changes.
Key Dates
| Date | Description |
|---|---|
| 09/02/2025 | Rule 10b5-1 trading plan adopted. |
| 03/25/2026 | Date of common stock transaction (sale). |
| 03/27/2026 | Date Form 4 was signed. |
Recommendation
holdThe reported sale by the CFO is a routine transaction executed under a Rule 10b5-1 plan, which was adopted several months prior. This type of pre-scheduled sale typically does not reflect a change in the executive's outlook on the company's future performance and is often for personal financial planning or diversification. Therefore, it does not provide a strong signal for a 'buy' or 'sell' recommendation, suggesting a 'hold' position is appropriate based solely on this filing.
Keywords
Apogee Therapeutics, APGE, Insider Trading, Form 4, Jane Henderson, CFO, Stock Sale, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.